Clinical Trial Update: Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease [Phase 2]

View source ↗

Summary

Phase 2 trial update for Batefenterol/Fluticasone Furoate in chronic obstructive pulmonary disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Batefenterol/Fluticasone Furoate

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 2 | Status: COMPLETED | Results posted: 2017-03-28